Loading...
Market
How many new therapies will Prime Medicine announce under the Bristol Myers Squibb collaboration by the end of 2024?
2
Resolution / Starting Odds
1 therapy • 25%
2 therapies • 25%
3 therapies • 25%
More than 3 therapies • 25%
Official press releases from Prime Medicine or Bristol Myers Squibb, corporate presentations
Story
Prime Medicine ($PRME) Partners with Bristol Myers Squibb ($BMY) in $3.5B Deal
Sep 30, 2024, 11:05 AM
Prime Medicine ($PRME) has announced a strategic research collaboration and license agreement with Bristol Myers Squibb ($BMY) to develop and commercialize multiple Prime Edited Ex Vivo T-Cell therapies. Under the terms of the agreement, Prime Medicine will receive $110 million upfront and could potentially earn more than $3.5 billion in milestone payments. This partnership aims to advance Prime Medicine's proprietary pipeline, which has been strategically focused to ensure a cash runway into the first half of 2026. The collaboration marks a significant step for Prime Medicine, founded by David Liu, as it navigates the complexities of translating scientific breakthroughs into treatments.
View original story
Similar markets
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
1-2 projects • 25%
3-4 projects • 25%
5-6 projects • 25%
More than 6 projects • 25%
Yes • 50%
No • 50%
Less than $100 million • 25%
$100 million to $299 million • 25%
$300 million to $499 million • 25%
$500 million or more • 25%
Q1 2026 • 25%
Q2 2026 • 25%
Q3 2026 • 25%
Q4 2026 or later • 25%
Yes • 50%
No • 50%
More than 3 new drugs • 25%
2-3 new drugs • 25%
1 new drug • 25%
No new drugs • 25%
Q1 2025 • 25%
Q2 2025 • 25%
Q3 2025 • 25%
Q4 2025 or later • 25%
0-1 • 25%
2-3 • 25%
4-5 • 25%
More than 5 • 25%
1-3 drugs/vaccines • 25%
4-6 drugs/vaccines • 25%
7-9 drugs/vaccines • 25%
10 drugs/vaccines • 25%